The Healthcare Data

Corcept Announces Positive CATALYST Trial Results

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company focused on developing medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating cortisol, announced today that the primary endpoint was met in the treatment phase of CATALYST. This randomized,…